Can Chronic-Phase Chronic Myeloid Leukemia Patients Achieve Optimal and Durable Responses after Two Failed TKI Treatments? Real-World Evidence Data
Acta Haematol
.
2019;142(2):61-63.
doi: 10.1159/000496449.
Epub 2019 May 21.
Author
Massimo Breccia
1
Affiliation
1
Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, "Sapienza" University, Rome, Italy, breccia@bce.uniroma1.it.
PMID:
31112953
DOI:
10.1159/000496449
No abstract available
Publication types
Editorial
Comment
MeSH terms
Dasatinib
Humans
Leukemia, Myeloid, Chronic-Phase*
Protein Kinase Inhibitors
Substances
Protein Kinase Inhibitors
Dasatinib